Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fernando, N. H.
Right arrow Articles by Hurwitz, H. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fernando, N. H.
Right arrow Articles by Hurwitz, H. I.
The Oncologist, Vol. 9, Suppl 1, 11–18, June 1, 2004
© 2004 AlphaMed Press

Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab

Nishan H. Fernando, Herbert I. Hurwitz

Department of Medical Oncology and Transplantation, Duke University Medical Center, Durham, North Carolina, USA

Correspondence: Herbert I. Hurwitz, M.D., Department of Medical Oncology and Transplantation, Box 3052, Duke University Medical Center, Durham, North Carolina 27710, USA. Telephone: 919-681-5257; Fax: 919-684-9712; e-mail: hurwi004{at}mc.duke.edu

Advanced colorectal cancer remains an urgent health concern, despite improvements in systemic chemotherapy. Targeted therapeutics promise effective tumor therapy with minimal side effects. Angiogenesis (the formation of new blood vessels) is essential for tumor growth and metastasis and may be an ideal target in the search for new antineoplastic agents. Vascular endothelial growth factor is one of the best characterized of the proangiogenic growth factors that regulate angiogenesis and is a logical target in colorectal cancer therapy. Bevacizumab (AvastinTM; Genentech Inc.; South San Fransisco, CA), a humanized murine monoclonal antibody directed at vascular endothelial growth factor, is being evaluated in the treatment of various types of cancer. It has shown promising efficacy in phase II clinical trials in patients with metastatic colorectal cancer. Addition of bevacizumab at a dose of 5 mg/kg to chemotherapy (5-fluorouracil plus leucovorin) resulted in a higher objective response rate (40% versus 17%), longer time to disease progression (9.0 versus 5.2 months), and longer median survival time (21.5 versus 13.8 months). Hypertension and thrombosis were the principal safety concerns, but were manageable. Further phase II/III studies of bevacizumab, administered with 5-fluorouracil plus leucovorin, with or without irinotecan and/or oxaliplatin, in colorectal cancer, are under way.

Key Words. Colorectal cancer • Clinical trial • Bevacizumab • Vascular endothelial growth factor • Monoclonal antibodies




This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
J. Yang, A. Ahmed, E. Poon, N. Perusinghe, A. de Haven Brandon, G. Box, M. Valenti, S. Eccles, K. Rouschop, B. Wouters, et al.
Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1{alpha} and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia
Mol. Cell. Biol., April 15, 2009; 29(8): 2243 - 2253.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Correale, P. Tagliaferri, A. Fioravanti, M. T. Del Vecchio, C. Remondo, F. Montagnani, M. S. Rotundo, C. Ginanneschi, I. Martellucci, E. Francini, et al.
Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial)
Clin. Cancer Res., July 1, 2008; 14(13): 4192 - 4199.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
R. P A Manzano, G. A Peyman, P. Khan, P. E Carvounis, M. Kivilcim, M. Ren, J. C Lake, and P. Chevez-Barrios
Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)
Br J Ophthalmol, June 1, 2007; 91(6): 804 - 807.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R. K Barakat, N. Singh, R. Lal, R. R Verani, K. W Finkel, and J. R Foringer
Interstitial Nephritis Secondary to Bevacizumab Treatment in Metastatic Leiomyosarcoma
Ann. Pharmacother., April 1, 2007; 41(4): 707 - 710.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Dincer and K. Altundag
Angiotensin-Converting Enzyme Inhibitors for Bevacizumab-Induced Hypertension
Ann. Pharmacother., December 1, 2006; 40(12): 2278 - 2279.
[Full Text] [PDF]

Home page
 The OncologistHome page
R. M. Goldberg
Therapy for Metastatic Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 981 - 987.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Lin, A. S. Lalani, T. C. Harding, M. Gonzalez, W.-W. Wu, B. Luan, G. H. Tu, K. Koprivnikar, M. J. VanRoey, Y. He, et al.
Inhibition of Lymphogenous Metastasis Using Adeno-Associated Virus-Mediated Gene Transfer of a Soluble VEGFR-3 Decoy Receptor
Cancer Res., August 1, 2005; 65(15): 6901 - 6909.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. X. Chen
Expanding the Clinical Development of Bevacizumab
Oncologist, June 1, 2004; 9(suppl_1): 27 - 35.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2004 by AlphaMed Press.
Advertisement